Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Change in Cash: 2020-2024

Historic Change in Cash for Monte Rosa Therapeutics (GLUE) over the last 5 years, with Dec 2024 value amounting to $96.4 million.

  • Monte Rosa Therapeutics' Change in Cash rose 728.35% to $138.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $82.8 million, marking a year-over-year increase of 23.77%. This contributed to the annual value of $96.4 million for FY2024, which is 33.03% up from last year.
  • According to the latest figures from FY2024, Monte Rosa Therapeutics' Change in Cash is $96.4 million, which was up 33.03% from $72.5 million recorded in FY2023.
  • In the past 5 years, Monte Rosa Therapeutics' Change in Cash registered a high of $308.5 million during FY2021, and its lowest value of -$291.2 million during FY2022.
  • Its 3-year average for Change in Cash is -$40.8 million, with a median of $72.5 million in 2023.
  • Its Change in Cash has fluctuated over the past 5 years, first spiked by 817.80% in 2021, then tumbled by 194.38% in 2022.
  • Yearly analysis of 5 years shows Monte Rosa Therapeutics' Change in Cash stood at $33.6 million in 2020, then surged by 817.80% to $308.5 million in 2021, then plummeted by 194.38% to -$291.2 million in 2022, then soared by 124.89% to $72.5 million in 2023, then skyrocketed by 33.03% to $96.4 million in 2024.